Internal tandem duplications of Flt3 gene (Flt3/IDT) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia

Leukemia and Lymphoma

Volumn 45, Issue 1, 2004, Pages 73-78

  Ciolli, S ^a   Vannucchi, A M ^a   Leoni, F ^a   Nozzoli, C ^a   Longo, G ^a   Salati, A ^a   Pancrazzi, A ^a   Bianchi, L ^a   Gigli, F ^a   Bosi, A ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Acute myeloid leukemia; Cytogenetic; Flt3; Prognostic factors; Transplantation

Indexed keywords

CYTARABINE; ETOPOSIDE; FLT3 LIGAND; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE DUPLICATION; GENE MUTATION; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SAMPLE SIZE;

ACUTE DISEASE; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENES, DUPLICATE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 10744222892     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000151851     Document Type: Article

References (23)

1. Lowenberg, B., Downing, J.R. and Burnett, A.K. (1999) "Acute myeloid leukemia", New England Journal of Medicine, 341(14), 1051-1062.
2. Harousseau, J.L. (1998) "Acute myeloid leukemia in the elderly", Blood Review, 12(3), 145-153.
3. Wheatley, K., Burnett, A.K., Goldstone, A.H., Gray, R.G., Hann, I.M., Harrison, C.J., et al. (1999) "A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom medical Research Council's Adult and Childhood Leukaemia Working Parties", British Journal of Haematology, 107(1), 69-79.
4. Ferrara, F. and Mirto, S. (1996) "Serum LDH as a predictor of clinicla outcome in acute myelogenous leukaemia of the eldelry", British Journal of Haematology, 92(3), 627-631.
5. Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, KS., Mohamed, A., et al. for the South Oncology Group and the Eastern Cooperative Oncology Group. (2000) "Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative oncology group study", Blood, 96(13), 4075-4083.
6. Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., et al. (1999) "Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia", Blood, 93(9), 3074-3080.
7. Rombouts, W.J., Blokland, I., Lowenberg, B. and Ploemacher, R.E. (2000) "Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene", Leukemia, 14(4), 675-683.
8. Fröhling, S., Schlenk, R.F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., et al. (2002) "Prognostic significance of FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics. A study of the AML Study Group ULM", Blood, 100(13), 4372-4380.
9. Kainz, B., Heintel, D., Marculescu, R., Scwarzinger, I., Sperr, W., Le, T., et al. (2002) "Variable prognostic value of flt3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16)", Hematological Journal, 3(6), 283-289.
10. Kiyoi, H. and Naoe, T. (2002) "FLT3 in human hematologic malignancies", Leukemia and Lymphoma, 43(8), 1541-1547.
11. Levis, M., Tse, K.F., Smith, D., Garrett, E. and Small, D. (2001) "A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations", Blood, 98(3), 885-887.
12. Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L. and Gilliland, D. (2002) "FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model", Blood, 99(1), 310-318.
13. Estey, E., Plunkett, W., Gandhi, V., Rios, M., Kantarjian, H. and Keating, M. (1993) "Fludarabine and arabinosylcytosine therapy for refractory and relapsed acute myelogenous leukemia", Leukemia and Lymphoma, 9(4-5), 343-350.
14. Mitelman, F. (ed) ISCN (1995) An International System for Human Cytogenetic Nomenclature. Basel: S. Karger.
15. Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S., Harrison, C.J., et al. on behalf of the Medical Research Council Adult Leukemia Working Party. (2001) "The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom research Council AML11 Trial", Blood, 98(5), 1312-1320.
16. Schoch, C., Haase, D., Haferlach, T., Gudat, H., Buchner, T., Freund, M., et al. (1996) "Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22):an additional deletion in 9q is an adverse prognostic factor", Leukemia, 10(8), 1288-1295.
17. Kaplan, E.L. and Meier, P. (1958) "Nonparametric estimation from incomplete observation", Journal of the American Statistical Association, 53, 457-481.
18. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., et al. (1977) "Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples", British Journal of Cancer, 35(1), 1-39.
19. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., et al. (2001) "The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk groups and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials", Blood, 98(6), 1752-1759.
20. Stirewall, D.L., Kopechy, K.J., Meshinchi, S., Appelbaum, F.R., Slovak, M.L., Willman, C.L., et al. (2001) "FLT3, RAS, TP53 mutations in elderly patients with acute myeloid leukemia", Blood, 97(11), 3589-3595.
21. Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., et al. (2002) "Analysis of FLT3 lenght mutation in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AML G study and usefulness as marker for the detection of minimal residual disease", Blood, 100(1), 59-66.
22. Boissel, N., Cayuela, J.M., Preudhomme, C., Thomas, X., Grardel, N., Fund, X., et al. (2002) "Prognostic significance of FLT3 internal tandem repeat in patients wiyh de novo acute myeloid leukemia with reinforced courses of chemotherapy", Leukemia, 16(9), 1699-1704.
23. Martinelli, G., Piccaluga, P. and Lo Coco, F. (2003) "FLT3 inhibition as tailored therapy for acute myeloid leukemia", Haematologica, 88(1), 4-7.